EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma


Por: Khoubai, FZ, Calovoulos, A, Guillorit, H, Carrillo-Reixach, J, del Rio-Alvarez, A, Klein, P, Coma, MS, Avignon, C, Rousseau, B, Charrot, LM, Fedou, S, Dupuy, JW, Royo, L, Domingo-Sàbat, M, Thézé, N, Siegfried, G, Khatib, AM, Cairo, S, Indersie, E, Jain, BP, Trézéguet, V, Gontier, E, Lamoureux, F, Guettier, C, Mussini, C, Hagedorn, M, Armengol, C and Grosset, CF

Publicada: 23 feb 2026
Resumen:
Background EZH2 is a histone methyltransferase and a key component of polycomb repressive complex 2 (PRC2). It plays a critical role in genome remodeling, gene regulation and acts through PRC2-dependent and independent mechanisms, which comprise methylation of histone and non-histone substrates, and transcriptional activation through different transcriptional complexes. EZH2 is involved in many cancers, but its role in hepatoblastoma is poorly understood. Methods Potential correlation between EZH2 mRNA expression and clinical parameters was analyzed by computational and histological approaches using seven published transcriptomic datasets and tissue samples from patients with hepatoblastoma. EZH2 molecular function was deciphered using molecular approaches, gain- and loss-of-function genetic tools, proteomics, immunohistochemistry, pharmacological drugs, 2D cell- and spheroid-based assays, and four different animal models. Results Our data show that EZH2 mRNA expression correlated with poor prognostic markers such as tumor proliferation, and patients' death and shorter survival. EZH2 protein potentiated hepatoblastoma cell proliferation, migration, survival and cisplatin resistance through its histone methyltransferase activity by repressing DUSP5, and transcriptionally inducing DUSP9 and HMGCR. In vivo EZH2 sustained tumor cell proliferation, and tumor development and angiogenesis. The EZH2 inhibitor GSK126 synergized with HMG-CoA reductase inhibitor statins to eradicate hepatoblastoma cells in vitro and block tumor development in mice. This combination was also very effective on various hepatoblastoma and non-hepatoblastoma tumor cell lines. Conclusion Collectively, our data showed that the protein EZH2 promotes hepatoblastoma development, partly through its histone methyltransferase activity, by differentially modulating the expression of DUSP5, DUSP9 and HMGCR genes and by supporting the MAPK/ERK pathway in hepatoblastoma cells already displaying high Wnt signal activity. EZH2 inhibitors triggered lipid synthesis in hepatoblastoma cells and synergized with cholesterol-lowering statins to block hepatoblastoma development in vitro and in vivo. Therefore, we demonstrate the key role of EZH2 in proliferative hepatoblastoma and the therapeutic benefit of combining EZH2 inhibitor and statin to treat patients with cancer.

Filiaciones:
Khoubai, FZ:
 Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France

 Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France

Calovoulos, A:
 Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France

 Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France

 Univ Bordeaux, Bordeaux Imaging Ctr, INSERM, CNRS,UMS 3420, F-33000 Bordeaux, France

Guillorit, H:
 Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France

Carrillo-Reixach, J:
 Germans Trias & Pujol Res Inst IGTP, Childhood Liver Oncol Grp, Badalona, Spain

 Networking Biomed Res Ctr CIBER Hepat & Digest Dis, Barcelona, Spain

Klein, P:
 Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France

 Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France

Coma, MS:
 Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France

Avignon, C:
 Bicetre Univ Hosp, AP HP, Dept Pathol, F-94275 Le Kremlin Bicetre, France

Rousseau, B:
 Univ Bordeaux, Serv Commun Anim, Dept STS, Anim A2, F-33000 Bordeaux, France

Charrot, LM:
 Univ Bordeaux, Serv Commun Anim, Dept STS, Anim A2, F-33000 Bordeaux, France

Fedou, S:
 Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France

 Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France

 Univ Bordeaux, Xenofish Platform, F-33000 Bordeaux, France

Dupuy, JW:
 Univ Bordeaux, Bordeaux Proteome, F-33000 Bordeaux, France

Royo, L:
 Germans Trias & Pujol Res Inst IGTP, Childhood Liver Oncol Grp, Badalona, Spain

Domingo-Sàbat, M:
 Germans Trias & Pujol Res Inst IGTP, Childhood Liver Oncol Grp, Badalona, Spain

Thézé, N:
 Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France

 Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France

Siegfried, G:
 Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France

 Univ Bordeaux, Xenofish Platform, F-33000 Bordeaux, France

Khatib, AM:
 Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France

 Univ Bordeaux, Xenofish Platform, F-33000 Bordeaux, France

Cairo, S:
 XenTech SAS, Genopole Campus,1-3 impasse Alexis Trinquet, F-91000 Evry, France

 Champ Oncol Inc, Baltimore, MD USA

 Ist Ric Pediat, Padua, Italy

Indersie, E:
 XenTech SAS, Genopole Campus,1-3 impasse Alexis Trinquet, F-91000 Evry, France

Jain, BP:
 Mahatma Gandhi Cent Univ, Dept Zool, Motihari, Bihar, India

Trézéguet, V:
 Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France

 Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France

Gontier, E:
 Univ Bordeaux, Bordeaux Imaging Ctr, INSERM, CNRS,UMS 3420, F-33000 Bordeaux, France

Lamoureux, F:
 Nantes Univ, Team CHILD 9, INSERM, CNRS UMR 6075,UMR 1307,CRCI2NA, F-44000 Nantes, France

Guettier, C:
 Bicetre Univ Hosp, AP HP, Dept Pathol, F-94275 Le Kremlin Bicetre, France

Mussini, C:
 Bicetre Univ Hosp, AP HP, Dept Pathol, F-94275 Le Kremlin Bicetre, France

Hagedorn, M:
 Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France

 Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France

:
 Germans Trias & Pujol Res Inst IGTP, Childhood Liver Oncol Grp, Badalona, Spain

 Networking Biomed Res Ctr CIBER Hepat & Digest Dis, Barcelona, Spain

Grosset, CF:
 Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France

 Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France

 Univ Bordeaux, MIRCADE Team, INSERM, U1312, 146 Rue Leo Saignat, F-33000 Bordeaux, France
ISSN: 14764598





Molecular Cancer
Editorial
BioMed Central, CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 25 Número: 1
Páginas:
WOS Id: 001719420500001
ID de PubMed: 41731536
imagen Green Submitted, gold

MÉTRICAS